Brought to you by 
Sanofi licenses global rights to Ardelyx’s phosphate transport program; deal ends
03 Feb 2023
Executive Summary
Ardelyx Inc. (developing therapies that target gut transporters and receptors for cardiorenal, metabolic, and gastrointestinal diseases) granted Sanofi worldwide rights to its phosphate transport NaP2b inhibitor program, including lead preclinical candidate RDX002.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sanofi licenses global rights to Ardelyx’s phosphate transport program; deal ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice